Summary of Study ST003049

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001899. The data can be accessed directly via it's Project DOI: 10.21228/M88147 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003049
Study TitlePlasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 2/3 - Eicosadomics of isolated platelets)
Study SummaryMetabolomics is an emerging and powerful molecular profiling method supporting clinical investigations. Serum and plasma are commonly used without rational prioritization. Serum is collected after blood coagulation, a complex biochemical process involving active platelet metabolism. This may affect the metabolome and increase the variance as platelet counts and function may vary substantially in individuals. A multi-omics approach systematically investigating the suitability of serum and plasma for clinical studies demonstrated that metabolites correlated well (n=461, R2=0.991), whereas lipid mediators (n=104, R2=0.906) and proteins (n=322, R2=0.860) differed substantially between specimen. Independently, analysis of platelet releasates identified most biomolecules significantly enriched in serum when compared to plasma. A prospective, randomized, controlled parallel group metabolomics trial with acetylsalicylic acid administered for 7 days demonstrated that the apparent drug effects significantly differ depending on analyzed specimen. Only serum analyses of healthy individuals suggested a significant downregulation of TXB2 and 12-HETE, which were specifically formed during coagulation in vitro. Plasma analyses reliably identified acetylsalicylic acid effects on metabolites and lipids occurring in vivo such as a decrease in polyunsaturated fatty acids. The present data suggests that plasma should be preferred above serum for clinical metabolomics studies as the serum metabolome may be substantially confounded by platelets.
Institute
University of Vienna
DepartmentDepartment of Analytical Chemistry
LaboratoryGerner lab
Last NameHagn
First NameGerhard
AddressWähringerstraße 38, 1090 Vienna, Austria
Emailgerhard.hagn@univie.ac.at
Phone+43 1 4277 52375
Submit Date2024-01-22
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2024-04-12
Release Version1
Gerhard Hagn Gerhard Hagn
https://dx.doi.org/10.21228/M88147
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA331236Platelets_Donor_10_con_1Control
SA331237Platelets_Donor_9_con_1Control
SA331238Platelets_Donor_8_con_1Control
SA331239Platelets_Donor_10_con_2Control
SA331240Platelets_Donor_8_con_2Control
SA331241Platelets_Donor_11_con_2Control
SA331242Platelets_Donor_1_con_1Control
SA331243Platelets_Donor_12_con_2Control
SA331244Platelets_Donor_12_con_1Control
SA331245Platelets_Donor_7_con_2Control
SA331246Platelets_Donor_11_con_1Control
SA331247Platelets_Donor_9_con_2Control
SA331248Platelets_Donor_3_con_1Control
SA331249Platelets_Donor_3_con_2Control
SA331250Platelets_Donor_2_con_2Control
SA331251Platelets_Donor_7_con_1Control
SA331252Platelets_Donor_1_con_2Control
SA331253Platelets_Donor_4_con_1Control
SA331254Platelets_Donor_2_con_1Control
SA331255Platelets_Donor_6_con_2Control
SA331256Platelets_Donor_4_con_2Control
SA331257Platelets_Donor_5_con_2Control
SA331258Platelets_Donor_6_con_1Control
SA331259Platelets_Donor_5_con_1Control
SA331260Platelets_Donor_9_act_1Platelet activation
SA331261Platelets_Donor_9_act_2Platelet activation
SA331262Platelets_Donor_8_act_2Platelet activation
SA331263Platelets_Donor_8_act_1Platelet activation
SA331264Platelets_Donor_10_act_1Platelet activation
SA331265Platelets_Donor_12_act_1Platelet activation
SA331266Platelets_Donor_7_act_2Platelet activation
SA331267Platelets_Donor_12_act_2Platelet activation
SA331268Platelets_Donor_11_act_2Platelet activation
SA331269Platelets_Donor_11_act_1Platelet activation
SA331270Platelets_Donor_10_act_2Platelet activation
SA331271Platelets_Donor_1_act_1Platelet activation
SA331272Platelets_Donor_3_act_1Platelet activation
SA331273Platelets_Donor_3_act_2Platelet activation
SA331274Platelets_Donor_2_act_2Platelet activation
SA331275Platelets_Donor_2_act_1Platelet activation
SA331276Platelets_Donor_1_act_2Platelet activation
SA331277Platelets_Donor_4_act_1Platelet activation
SA331278Platelets_Donor_4_act_2Platelet activation
SA331279Platelets_Donor_6_act_2Platelet activation
SA331280Platelets_Donor_6_act_1Platelet activation
SA331281Platelets_Donor_5_act_2Platelet activation
SA331282Platelets_Donor_5_act_1Platelet activation
SA331283Platelets_Donor_7_act_1Platelet activation
Showing results 1 to 48 of 48
  logo